Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B

Table 1 Baseline condition description of 95 patients, n (%)/mean ± SD/median (Q1, Q3)

General information	TAF group (n = 45)	ETV group (n = 50)	Total (n = 95)	t/χ2 value	P value
Age, years	40.20 ± 11.08	41.74 ± 12.24	41.01 ± 11.67	0.640	0.524
Sex (male/female)	29/16	26/24	55/40	1.505	0.220
Compensated cirrhosis	10 (22.2)	8 (16.0)	18 (18.9)	0.597	0.440
Comorbidity rate	7 (15.6)	6 (12.0)	13 (13.7)	0.253	0.615
ALT	34.90 (19.40, 44.9)	30.80 (23.53, 39.25)	32.00 (21.7, 42.2)	0.160	0.873
HBV-DNA viral load (lg10)	4.47 ± 2.16	4.28 ± 1.84	4.38 ± 1.99	0.365	0.717
Serum calcium	2.33 ± 0.13	2.30 ± 0.15	2.32 ± 0.14	0.935	0.352
Serum phosphorus	1.12 ± 0.21	1.12 ± 0.19	1.11 ± 0.19	0.026	0.980
Serum 25-hydroxyvitamin D3	22.67 ± 7.98	24.96 ± 11.30	23.88 ± 9.90	1.122	0.265
Blood urea	5.08 (4.31, 5.64)	4.46 (3.65, 5.05)	4.61 (3.81, 5.44)	2.602	0.011
Serum creatinine	62.00 (53.00, 69.00)	58.00 (50.00, 63.00)	59.00 (50.00, 65.00)	1.314	0.192
Serum retinol-binding protein	38.70 (32.20, 45.60)	28.85 (26.18, 31.13)	31.20 (26.80, 38.00)	5.365	< 0.0001
Serum cystatin C	0.83 (0.79, 0.91)	0.76 (0.72, 0.81)	0.79 (0.75, 0.85)	3.822	0.0002
Urinary α1-microglobulin	6.36 (4.80, 9.31)	4.07 (1.82, 6.92)	5.62 (2.89. 8.38)	2.068	0.042
Urine N-acetyl-beta-D-glucosaminidase	7.73 (5.62, 10.5)	7.99 (3.50, 11.18)	7.73 (4.95, 11.11)	1.027	0.307
Urine cystatin	0.15 (0.10, 0.21)	0.14 (0.09, 0.20)	0.14 (0.09, 0.21)	0.347	0.729

TAF: Tenofovir alafenamide fumarate; ETV: Entecavir; ALT: Alanine aminotransferase; HBV: Hepatitis B virus.